The stock of Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) is a huge mover today! About 554,091 shares traded hands or 242.10% up from the average. Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) has declined 21.34% since March 9, 2016 and is downtrending. It has underperformed by 28.76% the S&P500.
The move comes after 8 months negative chart setup for the $418.96 million company. It was reported on Oct, 12 by Barchart.com. We have $5.16 PT which if reached, will make NASDAQ:ADAP worth $58.65 million less.
Analysts await Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) to report earnings on November, 11. They expect $-0.23 EPS, down 1,050.00% or $0.21 from last year’s $-0.02 per share. After $-0.31 actual EPS reported by Adaptimmune Therapeutics PLC – ADR for the previous quarter, Wall Street now forecasts -25.81% EPS growth.
According to Zacks Investment Research, “Adaptimmune Therapeutics plc is a biopharmaceutical company. The Company is focused on cancer immunotherapy products based on T-cell receptor platform. Adaptimmune Therapeutics plc is based in Abingdon, United Kingdom.”
More important recent Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) news were published by: Marketwatch.com which released: “Adaptimmune Therapeutics PLC ADR” on April 14, 2015, also Benzinga.com published article titled: “Stocks Hitting 52-Week Lows”, Quotes.Wsj.com published: “DOW JONES, A NEWS CORP COMPANY” on November 29, 2014. More interesting news about Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) was released by: Equitiesfocus.com and their article: “Adaptimmune Therapeutics PLC – ADR (NASDAQ:ADAP) Basic Net EPS Stands At $-0.3783” with publication date: September 17, 2016.
ADAP Company Profile
Adaptimmune Therapeutics plc, incorporated on December 03, 2014, is a clinical-stage biopharmaceutical company. The Firm is focused on cancer immunotherapy products based on its T-cell receptor (TCR) platform. The Firm has developed a platform that enables it to identify cancer targets in the form of peptides, which are short sequences of amino acids, find and genetically engineer TCRs, and produce TCR therapeutic candidates for administration to patients. The Firm develops TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.